Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn’s disease

References

• PeppercornMAGoldmanPThe role of intestinal bacteria in the metabolism of salicylazosulfapyridineJ Pharmacol Exp Ther197218135555624402374
   PubMed Web of Science ®Google Scholar
• PeppercornMAGoldmanPDistribution studies of salicylazosulfapyridine and its metabolitesGastroenterology19736422402454405598
   PubMed Web of Science ®Google Scholar
• Azad KhanAKPirisJTrueloveSCAn experiment to determine the active therapeutic moiety of sulphasalazineLancet19772804489289572239
   PubMed Web of Science ®Google Scholar
• De VosMVerdievelHSchoonjansRPraetMBogaertMBarbierFConcentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparationsGut19923310133813421446856
   PubMed Web of Science ®Google Scholar
• LauritsenKLaursenLSRask-MadsenJClinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II)Clin Pharmacokinet1990192941252199130
   PubMed Web of Science ®Google Scholar
• Staerk LaursenLStokholmMBukhaveKRask-MadsenJLauritsenKDisposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretionGut19903111127112762253912
   PubMed Web of Science ®Google Scholar
• WiltinkEHMulderCJStolkLMRietbroekRVerbeekCTytgatGNAbsorption of oral mesalazine-containing preparations and the influence of famotidine on the absorptionScand J Gastroenterol19902565795842359989
   PubMed Web of Science ®Google Scholar
• RijkMCvan SchaikAvan TongerenJHDisposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoeaScand J Gastroenterol199227108638681359629
   PubMed Web of Science ®Google Scholar
• CrottyBRosenbergWMAronsonJKJewellDPInhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel diseaseGut19923310135313571446859
   PubMed Web of Science ®Google Scholar
• CrottyBHoangPDaltonHRJewellDPSalicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expressionGut199233159641740279
   PubMed Web of Science ®Google Scholar
• Di PaoloMCMerrettMNCrottyBJewellDP5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferonGut19963811151198566837
   PubMed Web of Science ®Google Scholar
• MahidaYRLammingCEGallagherAHawthorneABHawkeyCJ5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel diseaseGut199132150541846838
   PubMed Web of Science ®Google Scholar
• RachmilewitzDKarmeliFSchwartzLWSimonPLEffect of amino-phenols (5-ASA and 4-ASA) on colonic interleukin-1 generationGut19923379299321353743
   PubMed Web of Science ®Google Scholar
• BruinKFHommesDWJansenJTytgatGNWouter ten CateJvan DeventerSJModulation of cytokine release from human monocytes by drugs used in the therapy of inflammatory bowel diseasesEur J Gastroenterol Hepatol1995787917957496871
   PubMed Web of Science ®Google Scholar
• StevensCLipmanMFabryS5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cellsJ Pharmacol Exp Ther199527213994067815356
   PubMed Web of Science ®Google Scholar
• EliakimRKarmeliFChorevMOkonERachmilewitzDEffect of drugs on colonic eicosanoid accumulation in active ulcerative colitisScand J Gastroenterol199227119689721455196
   PubMed Web of Science ®Google Scholar
• SchmidtCFelsTBaumeisterBVetterHThe effect of 5-aminosalicylate and para-aminosalicylate on the synthesis of prostaglandin E2 and leukotriene B4 in isolated colonic mucosal cellsCurr Med Res Opin19961374174258862941
   PubMed Web of Science ®Google Scholar
• GionchettiPGuarnieriCCampieriMScavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generationDig Dis Sci19913621741781671010
   PubMed Web of Science ®Google Scholar
• SandovalMLiuXMannickEEClarkDAMillerMJPeroxynitrite-induced apoptosis in human intestinal epithelial cells is attenuated by mesalamineGastroenterology19971135148014889352850
   PubMed Web of Science ®Google Scholar
• RousseauxCLefebvreBDubuquoyLIntestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gammaJ Exp Med200520181205121515824083
   PubMed Web of Science ®Google Scholar
• DengXTolstanovaGKhomenkoTMesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: Novel molecular mechanism for mesalamine’s therapeutic actionJ Pharmacol Exp Ther200933131071107819762547
   PubMed Web of Science ®Google Scholar
• KaufmanJGriffithsTASuretteMGNessSRiouxKPEffects of mesalamine (5-aminosalicylic acid) on bacterial gene expressionInflamm Bowel Dis200915798599619202572
   PubMed Web of Science ®Google Scholar
• SchroederKWTremaineWJIlstrupDMCoated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized studyN Engl J Med198731726162516293317057
   PubMed Web of Science ®Google Scholar
• SninskyCACortDHShanahanFOral mesalamine (Asacol®) for mildly to moderately active ulcerative colitis. A multicenter studyAnn Intern Med199111553503551863024
   PubMed Web of Science ®Google Scholar
• RachmilewitzDCoated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trialBMJ1989298666682862563951
   PubMed Web of Science ®Google Scholar
• GreenJRLoboAJHoldsworthCDBalsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator GroupGastroenterology1998114115229428213
   PubMed Web of Science ®Google Scholar
• LevineDSRiffDSPruittRA randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitisAm J Gastroenterol20029761398140712094857
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJDallaireCDelayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trialCan J Gastroenterol2007211282783418080055
   PubMed Web of Science ®Google Scholar
• HanauerSBSandbornWJKornbluthADelayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trialAm J Gastroenterol2005100112478248516279903
   PubMed Web of Science ®Google Scholar
• SandbornWJRegulaJFeaganBGDelayed-Release Oral Mesalamine 4.8 g/day (800 mg tablet) is Effective for Patients with Moderately Active Ulcerative ColitisGastroenterology2009 [Epub ahead of print]
   Google Scholar
• An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitisA randomized, placebo-controlled trial. The Mesalamine Study GroupAnn Intern Med199612422042118533995
   PubMed Web of Science ®Google Scholar
• d’AlbasioGPaciniFCamarriECombined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind studyAm J Gastroenterol1997927114311479219787
   PubMed Web of Science ®Google Scholar
• DewMJHughesPHarriesADWilliamsGEvansBKRhodesJMaintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acidBr Med J (Clin Res Ed)198228563471012
   PubMed Web of Science ®Google Scholar
• DewMJHarriesADEvansNEvansBKRhodesJMaintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouthBr Med J (Clin Res Ed)198328763842324
   PubMed Web of Science ®Google Scholar
• RileySAManiVGoodmanMJHerdMEDuttSTurnbergLAComparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitisGastroenterology1988946138313892896139
   PubMed Web of Science ®Google Scholar
• CourtneyMGNunesDPBerginCFRandomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitisLancet19923398804127912811349676
   PubMed Web of Science ®Google Scholar
• GreenJRGibsonJAKerrGDMaintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator groupAliment Pharmacol Ther19981212120712169882028
   PubMed Web of Science ®Google Scholar
• BakerDEMMX mesalamineRev Gastroenterol Disord20066314615216957657
   PubMedGoogle Scholar
• KammMASandbornWJGassullMOnce-daily, high-concentration MMX mesalamine in active ulcerative colitisGastroenterology200713216675 quiz 432–43317241860
   PubMed Web of Science ®Google Scholar
• KammMALichtensteinGRSandbornWJRandomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitisGut200857789390218272546
   PubMed Web of Science ®Google Scholar
• PranteraCKohnACampieriMClinical trial: Ulcerative colitis maintenance treatment with 5-ASA – a 1-year, randomized multicentre study comparing MMX with AsacolAliment Pharmacol Ther200930990891819678813
   PubMed Web of Science ®Google Scholar
• TremaineWJSchroederKWHarrisonJMZinsmeisterARA randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol®, in the treatment of symptomatic Crohn’s colitis and ileocolitisJ Clin Gastroenterol19941942782827876505
   PubMed Web of Science ®Google Scholar
• BergmanRParkesMSystematic review: the use of mesalazine in inflammatory bowel diseaseAliment Pharmacol Ther200623784185516573787
   PubMed Web of Science ®Google Scholar
• AkobengAKGardenerEOral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s DiseaseCochrane Database Syst Rev20051CD00371515674913
   PubMed Web of Science ®Google Scholar
• CammaCGiuntaMRosselliMCottoneMMesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variablesGastroenterology19971135146514739352848
   PubMed Web of Science ®Google Scholar
• CaprilliRAndreoliACapursoLOral mesalazine (5-aminosalicylic acid; Asacol®) for the prevention of post-operative recurrence of Crohn’s disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)Aliment Pharmacol Ther19948135438186345
   PubMed Web of Science ®Google Scholar
• CaprilliRCottoneMTonelliFTwo mesalazine regimens in the prevention of the post-operative recurrence of Crohn’s disease: a pragmatic, double-blind, randomized controlled trialAliment Pharmacol Ther200317451752312622760
   PubMed Web of Science ®Google Scholar
• DohertyGBennettGPatilSCheifetzAMossACInterventions for prevention of post-operative recurrence of Crohn’s diseaseCochrane Database Syst Rev20094CD00687319821389
   PubMed Web of Science ®Google Scholar
• SutherlandLMacdonaldJKOral 5-aminosalicylic acid for induction of remission in ulcerative colitisCochrane Database Syst Rev20062CD00054316625536
   PubMed Web of Science ®Google Scholar
• PopoolaJMullerAFPollockLO’DonnellPCarmichaelPStevensPLate onset interstitial nephritis associated with mesalazine treatmentBMJ199831771617957979740571
   PubMed Web of Science ®Google Scholar
• PardiDSTremaineWJSandbornWJMcCarthyJTRenal and urologic complications of inflammatory bowel diseaseAm J Gastroenterol19989345045149576439
   PubMed Web of Science ®Google Scholar
• SchreiberSHamlingJZehnterERenal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylateGut199764067617669245930
   PubMed Web of Science ®Google Scholar
• GisbertJPGonzalez-LamaYMateJ5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic reviewInflamm Bowel Dis20075135:62963817243140
   PubMed Web of Science ®Google Scholar
• Van StaaTPTravisSLeufkensHGLoganRF5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic studyGastroenterology2004612671733173915188168
   PubMed Web of Science ®Google Scholar
• WorldMJStevensPEAshtonMARainfordDJMesalazine-associated interstitial nephritisNephrol Dial Transplant199641146146218671848
   PubMed Web of Science ®Google Scholar
• GisbertJPLunaMGonzalez-LamaYEffect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up studyGastroenterol Hepatol200810318:47748418928745
   PubMedGoogle Scholar
• EadenJAAbramsKRMayberryJFThe risk of colorectal cancer in ulcerative colitis: a meta-analysisGut2001448452653511247898
   PubMed Web of Science ®Google Scholar
• van StaaTPCardTLoganRFLeufkensHG5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological studyGut2005115411:1573157815994215
   PubMed Web of Science ®Google Scholar
• EadenJAbramsKEkbomAJacksonEMayberryJColorectal cancer prevention in ulcerative colitis: a case-control studyAliment Pharmacol Ther20002142:14515310651654
   PubMed Web of Science ®Google Scholar
• TerdimanJPSteinbuchMBlumentalsWAUllmanTARubinDT5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel diseaseInflamm Bowel Dis20074134:36737117206695
   PubMed Web of Science ®Google Scholar
• VelayosFSTerdimanJPWalshJMEffect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studiesAm J Gastroenterol2005610061345135315929768
   PubMed Web of Science ®Google Scholar
• YenEFKaneSVLadabaumUCost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitisAm J Gastroenterol200812103123094310518775007
   PubMed Web of Science ®Google Scholar
• BucklandABodgerKThe cost-utility of high dose oral mesalazine for moderately active ulcerative colitisAliment Pharmacol Ther20081212811–121287129618808444
   PubMed Web of Science ®Google Scholar
• IrvineEJYehCHRamseyDStirlingALHigginsPDThe effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitisAliment Pharmacol Ther20081212811–121278128618808446
   PubMed Web of Science ®Google Scholar
• HigginsPDRubinDTKaulbackKSchoenfieldPSKaneSVSystematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flaresAliment Pharmacol Ther20092129324725718945258
   PubMed Web of Science ®Google Scholar
• RubinDTSiegelCAKaneSVImpact of ulcerative colitis from patients’ and physicians’ perspectives: Results from the UC: NORMAL surveyInflamm Bowel Dis2009415458158819067414
   PubMed Web of Science ®Google Scholar
• ShaleMJRileySAStudies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel diseaseAliment Pharmacol Ther200371518219119812869079
   PubMed Web of Science ®Google Scholar
• HawthorneABRubinGGhoshSReview article: medication non-adherence in ulcerative colitis – strategies to improve adherence with mesalazine and other maintenance therapiesAliment Pharmacol Ther2008627121157116618384664
   PubMed Web of Science ®Google Scholar
• CohenHDDasKMThe metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agentJ Clin Gastroenterol2006840Suppl 3S150S15416885699
   PubMed Web of Science ®Google Scholar
• CorinaldesiRStanghelliniVCremonCEffect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept studyAliment Pharmacol Ther2009830324525219438846
   PubMed Web of Science ®Google Scholar